This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
MapLight Therapeutics, Inc. (MPLT) registered up to 13,181,055 shares of voting common stock for resale by selling stockholders: 9,197,887 issued shares and 3,983,168 shares issuable upon exercise of outstanding pre-funded warrants. Upon effectiveness, the shares may be sold in the open market; selling stockholders may sell all, some or none.
MapLight is not selling shares and will receive no proceeds from stockholder resales. It will receive the $0.0001-per-share exercise price if pre-funded warrants are exercised for cash. The shares originated in a private placement that closed August 14, 2026, from which MapLight received approximately $150.0 million in gross proceeds before placement agent fees and estimated offering expenses.
The company describes Phase 2 development of lead candidate ML-007C-MA for schizophrenia and Alzheimer’s disease psychosis. Topline results from its VISTA Alzheimer’s disease psychosis trial are expected in the second half of 2027.
MapLight Therapeutics, Inc. (MPLT) filed Amendment No. 1 to a Form S-1 to register for resale up to 13,181,055 shares of voting common stock, consisting of 9,197,887 shares and 3,983,168 shares issuable upon exercise of outstanding pre-funded warrants issued in an August 2026 private placement. The amendment is primarily to correct the number of shares outstanding as of September 1, 2026 and does not register any additional securities. The selling stockholders, including entities such as Catalyst4, Inc. and other institutional investors, may sell their shares from time to time through various methods, and MapLight will not receive proceeds from these resales, other than any nominal cash proceeds if the pre-funded warrants are exercised at their $0.0001 per share exercise price. As context, MapLight previously received approximately $150.0 million in gross proceeds from the private placement that created these securities and had 55,575,719 shares of common stock outstanding as of September 1, 2026.
MapLight Therapeutics, Inc. (MPLT) reported that its General Counsel, Kristopher Hanson, sold 16,509 shares of Voting Common Stock on September 16, 2026, at a weighted average price of $11.67 per share. The sale was made under a Rule 10b5-1 trading plan adopted on December 29, 2025, and Hanson held 137,044 shares directly after the transaction. The shares were sold in multiple trades at prices ranging from $11.38 to $12.17 per share.
MapLight Therapeutics, Inc. (MPLT) received a Form 144 notice from officer Kristopher Hanson covering a proposed sale of 16,509 shares of common stock through Jefferies LLC on NASDAQ under Rule 144. The shares were acquired from vested restricted stock units, and sales are pursuant to a Rule 10b5-1 selling plan adopted on December 29, 2025. The filing references 52,850,000 shares of common stock outstanding. In the prior three months, Hanson reported Rule 144 sales on July 15, 16, and 17, 2026.
MapLight Therapeutics, Inc. (MPLT) is registering for resale by existing investors up to 13,181,055 shares of voting common stock, including shares issuable upon exercise of pre-funded warrants, that were issued in an August 2026 private placement. The company itself is not selling shares in this registration and will not receive proceeds from selling stockholders’ sales, other than any nominal cash paid to exercise the pre-funded warrants.
MapLight is a clinical-stage biopharmaceutical company developing circuit-specific therapies for central nervous system disorders. Lead candidate ML-007C-MA, targeting M1/M4 muscarinic receptors, has shown positive topline Phase 2 results in schizophrenia (ZEPHYR), and the company plans an end-of-Phase 2 FDA meeting to discuss a Phase 3 trial supporting an initial NDA. A separate Phase 2 trial (VISTA) in Alzheimer’s disease psychosis is underway with topline results expected in the second half of 2027. Second product candidate ML-004 is in development for autism spectrum disorder symptoms, with Phase 2 results guiding upcoming regulatory discussions and potential partnerships.
The August 2026 private placement that created these resale shares raised $150.0 million in gross proceeds for MapLight through the sale of common stock and pre-funded warrants. As of September 1, 2026, there were 64,773,606 shares of common stock outstanding, and MPLT traded at $13.95 per share on September 8, 2026 on the Nasdaq Global Select Market. The prospectus notes that, once this registration is effective, the ability of selling stockholders to freely resell these shares could increase the volume of stock available for trading and affect the market price.
MapLight Therapeutics, Inc. (MPLT) is the subject of a Schedule 13G in which Nan Fung Group–affiliated reporting persons collectively report beneficial ownership, as reflected on Nan Fung Group Holdings Limited’s cover page, of 2,915,874 shares of common stock, representing 5.5% of the class.
The filing states that Pivotal bioVenture Partners Fund II, L.P. directly holds 611,446 shares, NFLS Beta Limited directly holds 671,606 shares, and Permwell Management Limited directly holds 1,628,722 shares of MapLight Therapeutics common stock. The ownership percentages are based on 52,848,208 voting common shares outstanding.
MapLight Therapeutics, Inc. (MPLT) reported that Chief Discovery Officer Anatol Kreitzer received equity awards on August 17, 2026. He was granted an option to purchase 24,455 shares of voting common stock at an exercise price of $11.245 per share, expiring August 16, 2036; 1/4 of the option vests on July 1, 2027 and 1/48 vests monthly thereafter, subject to continued service. He also received 6,020 RSUs, with 1/4 vesting on July 1, 2027 and 1/16 vesting on each subsequent October 1, January 1, April 1, and July 1, subject to continued service. Following these grants, he directly holds 180,926 shares of common stock.
MapLight Therapeutics, Inc. (MPLT) reported equity awards to its CAO and Interim CFO, Jonathan Gillis. On August 17, 2026 he received two stock option grants to purchase a total of 27,268 shares of voting common stock at an exercise price of $11.245 per share, expiring on August 16, 2036, with vesting in quarterly or monthly installments subject to continued service. He also received two restricted stock unit awards totaling 8,242 RSUs, each RSU representing one share of voting common stock, vesting over multi-year quarterly schedules, also contingent on continued service.
MapLight Therapeutics, Inc. (MPLT) reported that its Chief Scientific Officer, Lillie James Woodruff, received equity awards on August 17, 2026. She was granted an employee stock option covering 31,395 shares of voting common stock at an exercise price of $11.245 per share, expiring on August 16, 2036. According to the vesting terms, one quarter of the option shares vest on July 1, 2027, with 1/48th of the total shares vesting monthly thereafter, subject to her continued service.
On the same date she also received a restricted stock unit award covering 7,730 shares of voting common stock, with each RSU representing a contingent right to receive one share upon vesting. One quarter of these RSUs vest on July 1, 2027, and 1/16th vest on each subsequent October 1, January 1, April 1 and July 1, subject to continued service. Following this RSU grant, her direct holdings of voting common stock increased to 210,110 shares.